1 Title Page

2 3 4

3 Article Type: Research Article

- 5 Title: Potential impact of outpatient stewardship interventions on antibiotic exposures of
- 6 bacterial pathogens
- 7
- 8 Authors: Christine Tedijanto,¹ Yonatan H Grad,^{2,3} Marc Lipsitch^{1,2}
- 9
- 10 Author Affiliations: ¹ Center for Communicable Disease Dynamics, Department of
- 11 Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;
- ² Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
- 13 Health, Boston, Massachusetts, USA; ³ Division of Infectious Diseases, Brigham and Women's
- 14 Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 15
- 16 Corresponding Author: Christine Tedijanto, <u>ctedijanto@g.harvard.edu</u>
- 17
- 18 Manuscript Word Count: 3,025
- 19

20 Abstract

21 The relationship between antibiotic stewardship and population levels of antibiotic resistance 22 remains unclear. In order to better understand shifts in selective pressure due to stewardship, we 23 use publicly available data to estimate the effect of changes in prescribing on exposures to 24 frequently used antibiotics experienced by potentially pathogenic bacteria that are 25 asymptomatically colonizing the microbiome. We quantify this impact under four hypothetical 26 stewardship strategies. In one scenario, we estimate that elimination of all unnecessary outpatient 27 antibiotic use could avert 6 to 48% (IQR: 17 to 31%) of exposures across pairwise combinations 28 of sixteen common antibiotics and nine bacterial pathogens. All scenarios demonstrate that 29 stewardship interventions, facilitated by changes in clinician behavior and improved diagnostics, 30 have the opportunity to broadly reduce antibiotic exposures across a range of potential 31 pathogens. Concurrent approaches, such as vaccines aiming to reduce infection incidence, are 32 needed to further decrease exposures occurring in "necessary" contexts.

34 Introduction

35 Antibiotic consumption is a known driver of antibiotic resistance. In developed nations, over 80% of antibiotic consumption for human health occurs in the outpatient setting (European 36 37 Centre for Disease Prevention and Control, 2018; Public Health Agency of Canada, 2018; Public 38 Health England, 2017; Swedres-Svarm, 2017), and US-based studies conducted across different 39 subpopulations have estimated that 23-40% of outpatient prescriptions may be inappropriate 40 (Chua, Fischer, & Linder, 2019; Fleming-Dutra et al., 2016; Olesen, Barnett, MacFadden, 41 Lipsitch, & Grad, 2018). Inappropriate antibiotic use leads to increased risk of adverse events 42 (Linder, 2008; Shehab, Patel, Srinivasan, & Budnitz, 2008), disruption of colonization resistance 43 and other benefits of the microbial flora (Buffie & Pamer, 2013; Khosravi & Mazmanian, 2013), 44 and bystander selection for antibiotic resistance, with little to no health gains for the patient. 45 Recent work on bystander selection estimates that, for 8 of 9 potential pathogens of interest, over 46 80% of their exposures to commonly used antibiotic classes in the outpatient setting occur when 47 the organisms are asymptomatically colonizing the microbiome, not causing disease (Tedijanto, 48 Olesen, Grad, & Lipsitch, 2018). A corollary of extensive bystander selection is that reductions 49 in use will prevent antibiotic exposures for species throughout the microbiome.

50

We use publicly available data to quantify potentially avertable exposures of bacterial species to commonly used antibiotics under hypothetical changes in prescribing practice. The set of scenarios included here are intended as thought experiments to explore the upper bounds of avertable antibiotic exposures. Reductions in antibiotic consumption have historically had variable impacts on resistance levels, likely dependent on setting, baseline consumption and resistance patterns, and fitness costs (Andersson & Hughes, 2010; Lipsitch, 2001). In addition,

57	treatment strategies are primarily guided by randomized controlled trials assessing immediate
58	clinical outcomes, with less careful consideration given to the microbiome-wide effect of such
59	decisions. We apply analytical methods to parse out species-level effects of changes in
60	prescribing practice in order to better understand the potential impact of antibiotic stewardship.
61	
62	Methods
63	Scenarios of interest
64	This analysis includes sixteen antibiotics that are frequently prescribed in the outpatient setting
65	and nine potentially pathogenic bacterial species that are commonly carried in the normal human
66	microbiome. For each antibiotic-species pair, we estimate the proportion of antibiotic exposures
67	experienced by that species that could be averted under four hypothetical scenarios. The
68	scenarios range from broad elimination of unnecessary prescribing to focused modifications of
69	antibiotic use for specific indications as follows:
70	1) Eliminate unnecessary antibiotic use across all outpatient conditions.
71	2) Eliminate all antibiotic use for outpatient respiratory conditions for which antibiotics are
72	not indicated.
73	3) Eliminate all antibiotic use for acute sinusitis.
74	4) Prescribe nitrofurantoin for all cases of cystitis in women.
75	Based on previously published work, we consider viral upper respiratory tract infection,
76	influenza, non-suppurative otitis media, viral pneumonia, bronchitis, and allergy and asthma to
77	be outpatient respiratory conditions for which antibiotics are not indicated (Fleming-Dutra et al.,
78	2016). Due to the self-limiting nature and infrequent bacterial etiology of acute sinusitis, there is
79	weak evidence to support antibiotic treatment (Burgstaller, Steurer, Holzmann, Geiges, & Soyka,

80	2016; Rosenfeld et al., 2015). However, antibiotics continue to be prescribed at over 80% of US
81	outpatient visits with a primary diagnosis of acute sinusitis (Smith et al., 2013). In contrast,
82	antibiotics are always recommended for urinary tract infections (UTIs). Despite being
83	recommended as a second-line therapy for cystitis due to concerns about resistance,
84	fluoroquinolones are the most common treatment, prescribed at 40% of outpatient visits for
85	uncomplicated UTI (Kabbani et al., 2018). We explore the hypothetical scenario of treating all
86	cases of cystitis in women with nitrofurantoin, a recommended first-line therapy with good
87	potency against common uropathogens, low levels of resistance, and decreased risk of collateral
88	damage to the intestinal microbiome due to its propensity to concentrate in the bladder (Gupta et
89	al., 2011; Gupta, Scholes, & Stamm, 1999; Stewardson et al., 2015).
90	
91	Data sources and methodology
92	Extending our recent work on bystander selection (Tedijanto et al., 2018), we used the 2015
0.2	
93	National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care
93 94	National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey (NAMCS/NHAMCS), the Human Microbiome Project (HMP) (Huttenhower et al., 2012;
94	Survey (NAMCS/NHAMCS), the Human Microbiome Project (HMP) (Huttenhower et al., 2012;
94 95	Survey (NAMCS/NHAMCS), the Human Microbiome Project (HMP) (Huttenhower et al., 2012; The Human Microbiome Project Consortium, 2012), and assorted carriage and etiology studies
94 95 96	Survey (NAMCS/NHAMCS), the Human Microbiome Project (HMP) (Huttenhower et al., 2012; The Human Microbiome Project Consortium, 2012), and assorted carriage and etiology studies to estimate national outpatient antibiotic exposures by drug, species, and condition.
94 95 96 97	Survey (NAMCS/NHAMCS), the Human Microbiome Project (HMP) (Huttenhower et al., 2012; The Human Microbiome Project Consortium, 2012), and assorted carriage and etiology studies to estimate national outpatient antibiotic exposures by drug, species, and condition. NAMCS/NHAMCS are annual cross-sectional surveys designed to sample outpatient visits in
94 95 96 97 98	Survey (NAMCS/NHAMCS), the Human Microbiome Project (HMP) (Huttenhower et al., 2012; The Human Microbiome Project Consortium, 2012), and assorted carriage and etiology studies to estimate national outpatient antibiotic exposures by drug, species, and condition. NAMCS/NHAMCS are annual cross-sectional surveys designed to sample outpatient visits in the United States, and up to five diagnoses and thirty medications may be associated with each
94 95 96 97 98 99	Survey (NAMCS/NHAMCS), the Human Microbiome Project (HMP) (Huttenhower et al., 2012; The Human Microbiome Project Consortium, 2012), and assorted carriage and etiology studies to estimate national outpatient antibiotic exposures by drug, species, and condition. NAMCS/NHAMCS are annual cross-sectional surveys designed to sample outpatient visits in the United States, and up to five diagnoses and thirty medications may be associated with each visit. We used methodology developed by Fleming-Dutra and colleagues (Fleming-Dutra et al.,

103	(599.0), without a concurrent diagnosis of pyelonephritis (590.1, 590.8), renal abscess (590.2), or
104	kidney infection (590.9), were considered to be associated with cystitis. In this analysis, we
105	maintain the assumption that one antibiotic prescription is equivalent to one exposure; antibiotic
106	exposures experienced by a given species and associated with a given condition are roughly
107	estimated as the product of antibiotic prescriptions for that condition and species carriage
108	prevalence, which is dependent on disease etiology (target exposures) and asymptomatic carriage
109	prevalence (bystander exposures) (details in Appendix Table 1). For diagnoses where etiology
110	was not readily available, we assumed that none of our species of interest were causative agents.
111	These assumptions have been enumerated in detail in prior work (Tedijanto et al., 2018).
112	
113	We applied proportions of unnecessary antibiotic prescribing by condition and age group
114	estimated by Fleming-Dutra and colleagues based on expert opinion, clinical guidelines, and
115	regional variability in use (Fleming-Dutra et al., 2016). Since these estimates were reported for
116	oral antibiotic use in the outpatient setting, we excluded antibiotics that are typically
117	administered topically or parenterally. For relevant scenarios (1 and 2), we applied the
118	proportions of unnecessary use evenly across all antibiotic prescriptions.
119	
120	The proportion of avertable antibiotic exposures for each species is defined by Equation 1. The
121	equation adopts previously described notation (Tedijanto et al., 2018) with modifications. A
122	listing of all variables and descriptions can be found in Appendix Table 1. Let a represent
123	antibiotic, s represent species, i represent ICD-9-CM diagnosis code, and g represent age group.
124	Prescriptions with $i=0$ were not associated with any ICD-9-CM diagnosis codes, and throughout
125	the analysis we have weighted outpatient visits to be nationally representative. Let X_{as} be the

126 number of avertable exposures by antibiotic and species, T_{as} be the total number of exposures by 127 antibiotic and species, d_{aig} be the number of prescriptions of antibiotic *a* associated with diagnosis code i in age group g, p_{sig} be the carriage prevalence of species s among those with 128 diagnosis code i in age group g, and q_{aig} be the proportion of avertable exposures by diagnosis 129 130 code and age group in the given scenario. For example, in the scenario assessing elimination of 131 all unnecessary antibiotic use, q_{aig} is the proportion of avertable antibiotic use by diagnosis and 132 age group (Fleming-Dutra et al., 2016). Alternatively, in the scenario assessing elimination of 133 non-nitrofurantoin treatment for cystitis, q_{aig} is 1 when a is not nitrofurantoin and i is a diagnosis 134 code associated with cystitis, and 0 elsewhere. Carriage prevalences (p_{sig}) are assumed to be 135 constant within three age groups (under 1 year, 1-5 years, over 5 years old) (Tedijanto et al., 136 2018), while proportions of avertable antibiotic use (q_{aig}) were reported for three different age 137 groups (0-19 years, 20-64 years, 65 years old and over) (Fleming-Dutra et al., 2016). G is the 138 smallest set of age groups that accounts for this granularity (under 1 year, 1-5 years, 6-19 years, 139 20-64 years, 65 years old and over).

140 **Equation 1.** Proportion of avertable exposures by species and antibiotic.

$$\frac{X_{as}}{T_{as}} = \frac{\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig} \times q_{aig}}{\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig}}$$

In scenarios where unnecessary use is eliminated (1 and 2), we assume that only bystander exposures are affected. Equivalently, this presumes that perfect discrimination between bacterial and non-bacterial etiologies is possible. This results in a slight modification to Equation 1 -- p_{sig} is changed to p_{s0g} as all eliminated exposures would have occurred during asymptomatic carriage. For cases where e_{sig} is 1, we assume zero avertable exposures. In addition, we make slight modifications to q_{aig} when we estimate the proportion of bacterial cases to be larger than the proportion of necessary prescriptions (Appendix Table 2). As a sensitivity analysis, we

include the proportion of avertable exposures for each species-antibiotic pair under Scenario 1 if
antibiotic use was eliminated equally across both target and bystander exposures (Appendix

151 Figure 1). All analysis was conducted in R version 3.5.1.

152

153 Results

154 Results for all four scenarios are depicted in Figure 1. We estimate that elimination of

unnecessary antibiotic prescriptions across all outpatient conditions would prevent 6 to 48%

156 (IQR: 17 to 31%) of antibiotic-species exposures (Figure 1A). The smallest reduction is

associated with S. pyogenes exposures to cefdinir and the largest with H. influenzae and E. coli

158 exposures to azithromycin. If all unnecessary antibiotic use could be prevented, over 30% of

159 exposures to amoxicillin-clavulanate, penicillin, azithromycin, clarithromycin, levofloxacin, and

160 doxycycline across most potential pathogens of interest could be averted. As expected, the

161 proportion of avertable exposures when all unnecessary outpatient use is eliminated is positively


162 correlated with previously reported estimates of bystander selection (Appendix Figure 2)

163 (Tedijanto et al., 2018).

164

Across all scenarios, the proportion of avertable exposures appears to be primarily driven by the drug considered. For example, in both scenarios assessing broad elimination of unnecessary antibiotic use, every species can expect azithromycin exposures to decrease to the greatest extent as it is the most commonly used antibiotic for respiratory conditions for which antibiotics are not indicated (Figure 1B). The estimated reductions in azithromycin across species range from 37 to 48% when all outpatient conditions are considered and from 24 to 32% when limited to the subset of respiratory conditions for which antibiotics are not indicated. High estimates of

172 avertable exposures for a particular antibiotic reflect both frequent use for the impacted 173 syndrome(s) and concentrated use for those conditions relative to other indications. Consider the 174 indication-specific scenarios: ciprofloxacin and sulfamethoxazole-trimethoprim are the most 175 frequently prescribed antibiotics for cystitis other than nitrofurantoin and have relatively large 176 estimates of avertable exposures (23 to 44% and 7 to 26%, respectively). While clarithromycin is 177 only the eighth-most-prescribed antibiotic for acute sinusitis among the included antibiotics, its 178 concentrated use for acute sinusitis compared to other indications results in relatively large 179 expected reductions in exposure (up to 9% for P. aeruginosa and S. pyogenes) compared to other 180 drugs.



181

Figure 1. Heatmaps showing the estimated percentage of species exposures to each antibiotic or antibiotic class that could be averted if *A*: unnecessary antibiotic prescriptions across all outpatient conditions, *B*: all antibiotic use for outpatient respiratory conditions for which

185 antibiotics are not indicated, C: all antibiotic use for acute sinusitis, or D: non-nitrofurantoin

- treatment of cystitis in women was eliminated. Drug class results include prescriptions of all
- 187 antibiotics in that class, as identified by the Multum Lexicon classification system.
- 188 Abbreviations: Antibiotics (y-axis): AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,
- 189 AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,
- 190 CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,
- 191 TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin;
- 192 Organisms (x-axis): EC=E. coli, HI=H. influenzae, KP=K. pneumoniae, MC=M. catarrhalis, PA=P. aeruginosa,
- 193 SA=S. aureus, SAg=S. agalactiae, SP=S. pneumoniae, SPy=S. pyogenes; PY=person-years
- 194
- 195 Characteristics of the bacterial organism of interest also influence the extent of avertable
- 196 exposures. Species that are common causes of the affected condition(s) naturally have larger
- 197 predicted reductions in exposure. For example, an estimated 33%, 36%, and 44% of
- 198 ciprofloxacin exposures to E. coli, K. pneumoniae, and P. aeruginosa, respectively, could be
- 199 averted under the cystitis scenario, compared to 23 to 27% across all other organisms. Although
- 200 E. coli is the most common cause of UTIs, its estimated exposure reduction in this scenario is
- 201 lower than that of *P. aeruginosa*, likely due to the larger number of bystander exposures incurred
- 202 by *E. coli* during asymptomatic carriage. Infrequent carriage prevalence in the normal
- 203 microbiome is also generally associated with lower proportions of avertable exposures across all
- 204 antibiotics (e.g. S. pyogenes, S. agalactiae, M. catarrhalis).
- 205

206 Discussion

We quantify the species-level impact of changes in antibiotic consumption as the proportion of antibiotic exposures experienced by common bacterial pathogens that could be averted under four hypothetical scenarios. In the scenario where unnecessary antibiotic use for all outpatient conditions is eliminated, we find that up to 48% of exposures (of *H. influenzae* and *E. coli* to azithromycin) could be avoided. In addition, impact of the intervention across antibiotics and species is widespread, with half of antibiotic-species pairs expected to experience a reduction in exposures of over one fifth (22%). For conditions which require antibiotic treatment, such as

UTIs, switching to antibiotics with decreased collateral damage to the microbiome, such as nitrofurantoin, may be an effective strategy for reducing antibiotic exposures across species.

217 In three out of four situations we assess, antibiotics are considered entirely unnecessary for some 218 or all cases. This is a strong assumption in the case of acute sinusitis, as a small number of cases 219 are truly bacterial and antibiotics are indicated for patients with persistent, severe or worsening 220 symptoms (Rosenfeld et al., 2015). These scenarios are explored in sensitivity analyses 221 (Appendix Figure 3). In the future, this method may also be extended to measure net changes in 222 exposures resulting from more nuanced scenarios where one antibiotic is substituted for another. 223 We did not assess such changes for nitrofurantoin, as its effects on the microbiome outside of the 224 bladder are thought to be minimal (Stewardson et al., 2015). The reductions in use presented here 225 may be practically infeasible due to challenges including similar clinical presentation of viral and 226 bacterial infections, individual considerations such as allergies (Sakoulas, Geriak, & Nizet, 2018) 227 or heightened risk of adverse events, misdiagnosis (Filice et al., 2015; Tomas, Getman, Donskey, 228 & Hecker, 2015), and patient-driven demand (Vanden Eng et al., 2003). Even if elimination of 229 unnecessary use were fully realized, our results imply that the majority of species' antibiotic 230 exposures occur in the context of "necessary" antibiotic use. These findings underscore the 231 importance of considering bystander effects and the need for a multi-pronged approach to 232 programs aimed at controlling antibiotic resistance. Rapid diagnostics, diagnostics that 233 accurately discriminate between bacterial and non-bacterial causes, patient education, and 234 improved decision-making tools and other interventions to motivate changes in clinician 235 behavior can enhance responsible antibiotic consumption; these should be implemented 236 simultaneously with prevention measures such as infection control, access to clean water and

sanitation, safe sex interventions, and vaccination, which aim to reduce infection incidence andthus any antibiotic use.

239

240	At the time of this analysis, NHAMCS data from hospital outpatient departments was not yet
241	available for years after 2011. In the 2010-2011 NAMCS/NHAMCS data, visits to hospital
242	outpatient departments accounted for 36% of included sampled visits, but just 9% of all
243	antibiotic mentions. The proportions of avertable exposures including and excluding these visits
244	for 2010-2011 were similar (Appendix Figure 4); thus, we assumed that antibiotic use and
245	diagnoses in the existing 2015 data without hospital outpatient department visits was
246	representative. Additional limitations of the included datasets and method for estimating
247	antibiotic exposures have been previously enumerated (Tedijanto et al., 2018). Notably, the
248	NAMCS/NHAMCS does not provide information to link medications with diagnoses, so we
249	adopted a published tiered system to pair antibiotic use at each visit with the most likely
250	indication (Fleming-Dutra et al., 2016). For visits with multiple diagnoses, all antibiotic use was
251	attributed to the single most-likely indication. This method tends to overestimate antibiotic use
252	for conditions for which antibiotics are almost always indicated, which may lead to clinically
253	unusual diagnosis-treatment linkages. In the same way, antibiotic prescriptions are
254	underestimated for diagnoses for which antibiotic use is not indicated, potentially leading to
255	downward bias in avertable exposures for these conditions. Additionally, NAMCS/NHAMCS
256	antibiotic use data does not include prescription details such as duration or dose. However, the
257	correlation between these factors and selection for resistance requires further study; prescriptions
258	may be a sufficient measure (Bruyndonckx et al., 2014; Lipsitch, 2001).

259

260 At the time of this analysis, Fleming-Dutra et al. remained the most up-to-date source of 261 unnecessary antibiotic prescribing by condition. Recent work with slightly different methods 262 found a lower proportion of inappropriate antibiotic prescriptions overall (23.2% compared to 263 30%) but did not report their estimates by condition (Chua et al., 2019). Although comparable 264 estimates of unnecessary prescribing over time are unavailable, multiple studies have shown that 265 declines in antibiotic use from approximately 2011 to 2016 in the United States have been 266 primarily due to pediatric prescribing, implying that, at least for adults, levels of unnecessary 267 prescribing likely remained similar (Durkin et al., 2018; King, Bartoces, Fleming-Dutra, Roberts, 268 & Hicks, 2019; Klevens et al., 2019; Olesen et al., 2018). Finally, we assume that the proportion 269 of unnecessary use is constant across antibiotics used for the same condition as it is difficult to 270 identify specific antibiotic prescriptions that were unwarranted without detailed chart review. A 271 study among outpatients in the Veterans Affairs medical system found that among prescriptions 272 for community-acquired pneumonia, sinusitis, and acute exacerbations of chronic bronchitis, the 273 highest proportion of macrolide use was inappropriate (27%), followed by penicillins (22%) and 274 quinolones (12%) (Tobia, Aspinall, Good, Fine, & Hanlon, 2008). Similar studies are needed to 275 understand which antibiotics are frequently used inappropriately for other indications and 276 settings.

277

278 Reductions in antibiotic consumption are necessary to preserve the potency of these drugs.
279 Quantifying changes in species-level exposures due to stewardship programs is one more step
280 towards understanding how changes in antibiotic use correspond to antibiotic resistance at the
281 population level. Further research, integrating knowledge from clinical, ecological, and
282 evolutionary spheres, is needed to elucidate this relationship (MacLean & San Millan, 2019).

- 283 The methods presented here may be easily extended to incorporate other data sources, such as
- 284 claims, or to assess more specific stewardship programs. We show that while improved
- 285 prescribing practices have the potential to prevent antibiotic exposures experienced by bacterial
- 286 species throughout the microbiome, complementary efforts to facilitate appropriate antibiotic
- 287 consumption and decrease overall infection incidence are required to substantially avert
- 288 exposures.

289 Acknowledgements

- 290 We thank Dr. Lauri Hicks for her helpful comments on this manuscript.
- 291

292 **Competing Interests**

- 293 ML has received consulting income from Affinivax, Antigen Discovery, Merck, and Pfizer and
- 294 research grants through Harvard School of Public Health from Pfizer and PATH. YHG has
- 295 received consulting income from Merck and GlaxoSmithKline. The authors have no other
- relationships or activities that could appear to have influenced the submitted work.
- 297

298 Funding Sources

- 299 This work was supported by Grant U54GM088558 (Models of Infectious Disease Agent Study,
- 300 Center for Communicable Disease Dynamics) from the National Institute of General Medical
- 301 Sciences, Grant R01AI132606 from the National Institute of Allergy and Infectious Diseases (to
- 302 YHG), Grant CK000538-01 from the Centers for Disease Control and Prevention, and the Doris
- 303 Duke Charitable Foundation. CT is supported by Grant T32AI007535 from the National Institute
- 304 of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and
- 305 does not necessarily represent the official views of the National Institute of General Medical
- 306 Sciences, National Institutes of Health, National Institute of Allergy and Infectious Diseases,
- 307 Centers for Disease Control and Prevention, Department of Health and Human Services, or the
- 308 Doris Duke Charitable Foundation.
- 309
- 310

311 References

- 312
- 313 Aitken, M., & Taylor, J. A. (1998). Prevalence of Clinical Sinusitis in Young Children Followed
- 314 Up by Primary Care Pediatricians. *Archives of Pediatrics & Adolescent Medicine*, 152(3),
- 315 244–248. https://doi.org/10.1001/archpedi.152.3.244
- 316 Andersson, D. I., & Hughes, D. (2010). Antibiotic resistance and its cost: Is it possible to reverse
- 317 resistance? *Nature Reviews Microbiology*, 8(4), 260–271.
- 318 https://doi.org/10.1038/nrmicro2319
- 319 Benninger, M. S., Holzer, S. E. S., & Lau, J. (2000). Diagnosis and treatment of uncomplicated
- 320 acute bacterial rhinosinusitis: Summary of the Agency for Health Care Policy and
- 321 Research evidence-based report. *Otolaryngology–Head and Neck Surgery*, *122*(1), 1–7.
- 322 https://doi.org/10.1016/S0194-5998(00)70135-5
- 323 Bluestone, C. D., Stephenson, J. S., & Martin, L. M. (1992). Ten-year review of otitis media

324 pathogens. *The Pediatric Infectious Disease Journal*, 11(8), S7–S11.

325 https://doi.org/10.1097/00006454-199208001-00002

- 326 Brook, I. (2016). Microbiology of chronic rhinosinusitis. European Journal of Clinical
- 327 *Microbiology & Infectious Diseases*, 35(7), 1059–1068. https://doi.org/10.1007/s10096-
- 328 016-2640-x
- 329 Bruyndonckx, R., Hens, N., Aerts, M., Goossens, H., Molenberghs, G., & Coenen, S. (2014).
- 330 Measuring trends of outpatient antibiotic use in Europe: Jointly modelling longitudinal
- data in defined daily doses and packages. Journal of Antimicrobial Chemotherapy, 69(7),
- 332 1981–1986. https://doi.org/10.1093/jac/dku063

- 333 Buffie, C. G., & Pamer, E. G. (2013). Microbiota-mediated colonization resistance against
- intestinal pathogens. *Nature Reviews Immunology*, *13*(11), 790–801.
- 335 https://doi.org/10.1038/nri3535
- 336 Burgstaller, J. M., Steurer, J., Holzmann, D., Geiges, G., & Soyka, M. B. (2016). Antibiotic
- 337 efficacy in patients with a moderate probability of acute rhinosinusitis: A systematic
- 338 review. European Archives of Oto-Rhino-Laryngology, 273(5), 1067–1077.
- 339 https://doi.org/10.1007/s00405-015-3506-z
- Celin, S. E. (1991). Bacteriology of Acute Otitis Media in Adults. JAMA, 266(16), 2249–2252.
- 341 https://doi.org/10.1001/jama.266.16.2249
- 342 Chua, K.-P., Fischer, M. A., & Linder, J. A. (2019). Appropriateness of outpatient antibiotic
- prescribing among privately insured US patients: ICD-10-CM based cross sectional
 study. *BMJ*, *364*(k5092). https://doi.org/10.1136/bmj.k5092
- 345 Durkin, M. J., Jafarzadeh, S. R., Hsueh, K., Sallah, Y. H., Munshi, K. D., Henderson, R. R., &
- 346 Fraser, V. J. (2018). Outpatient Antibiotic Prescription Trends in the United States: A
- 347 National Cohort Study. *Infection Control & Hospital Epidemiology*, *39*(5), 584–589.
- 348 https://doi.org/10.1017/ice.2018.26
- European Centre for Disease Prevention and Control. (2018). *Antimicrobial consumption: Annual epidemiological report for 2017*. Stockholm.
- 351 Filice, G. A., Drekonja, D. M., Thurn, J. R., Hamann, G. M., Masoud, B. T., & Johnson, J. R.
- 352 (2015). Diagnostic Errors that Lead to Inappropriate Antimicrobial Use. *Infection Control*353 & *Hospital Epidemiology*, 36(8), 949–956. https://doi.org/10.1017/ice.2015.113
- 354 Fleming-Dutra, K. E., Hersh, A. L., Shapiro, D. J., Bartoces, M., Enns, E. A., File, T. M., ...
- 355 Hicks, L. A. (2016). Prevalence of Inappropriate Antibiotic Prescriptions Among US

- 356 Ambulatory Care Visits, 2010-2011. *JAMA*, *315*(17), 1864–1873.
- 357 https://doi.org/10.1001/jama.2016.4151
- 358 Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., ... Soper, D. E.
- 359 (2011). International Clinical Practice Guidelines for the Treatment of Acute
- 360 Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious
- 361 Diseases Society of America and the European Society for Microbiology and Infectious
- 362 Diseases. *Clinical Infectious Diseases*, 52(5), e103–e120.
- 363 https://doi.org/10.1093/cid/ciq257
- 364 Gupta, K., Scholes, D., & Stamm, W. E. (1999). Increasing prevalence of antimicrobial
- 365 resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA,

366 *281*(8), 736–738. https://doi.org/10.1001/jama.281.8.736

- 367 Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J. H., Chinwalla, A. T., ...
- 368 White, O. (2012). Structure, function and diversity of the healthy human microbiome.

369 *Nature*, 486(7402), 207–214. https://doi.org/10.1038/nature11234

- 370 Kabbani, S., Hersh, A. L., Shapiro, D. J., Fleming-Dutra, K. E., Pavia, A. T., & Hicks, L. A.
- 371 (2018). Opportunities to Improve Fluoroquinolone Prescribing in the United States for
- Adult Ambulatory Care Visits. *Clinical Infectious Diseases*, 67(1), 134–136.
- 373 https://doi.org/10.1093/cid/ciy035
- 374 Khosravi, A., & Mazmanian, S. K. (2013). Disruption of the gut microbiome as a risk factor for
- 375 microbial infections. *Current Opinion in Microbiology*, *16*(2), 221–227.
- 376 https://doi.org/10.1016/j.mib.2013.03.009

- 377 King, L. M., Bartoces, M., Fleming-Dutra, K. E., Roberts, R. M., & Hicks, L. A. (2019).
- 378 Changes in US Outpatient Antibiotic Prescriptions from 2011-2016. *Clinical Infectious*
- 379 Diseases. https://doi.org/10.1093/cid/ciz225
- 380 Klevens, R. M., Caten, E., Olesen, S. W., DeMaria, A., Troppy, S., & Grad, Y. H. (2019).
- 381 Outpatient antibiotic prescribing in Massachusetts, 2011-2015. *Open Forum Infectious*
- 382 *Diseases*, *6*(5), ofz169. https://doi.org/10.1093/ofid/ofz169
- 383 Linder, J. A. (2008). Editorial Commentary: Antibiotics for Treatment of Acute Respiratory
- 384 Tract Infections: Decreasing Benefit, Increasing Risk, and the Irrelevance of
- 385 Antimicrobial Resistance. *Clinical Infectious Diseases*, 47(6), 744–746.
- 386 https://doi.org/10.1086/591149
- 387 Lipsitch, M. (2001). The rise and fall of antimicrobial resistance. *Trends in Microbiology*, 9(9),

388 438–444. https://doi.org/10.1016/S0966-842X(01)02130-8

389 MacLean, R. C., & San Millan, A. (2019). The evolution of antibiotic resistance. Science,

390 *365*(6458), 1082–1083. https://doi.org/10.1126/science.aax3879

- 391 Olesen, S. W., Barnett, M. L., MacFadden, D. R., Lipsitch, M., & Grad, Y. H. (2018). Trends in
- 392 outpatient antibiotic prescribing practice among US older adults, 2011-2015: An
- 393 observational study. *BMJ*, *362*, k3155. https://doi.org/10.1136/bmj.k3155
- Public Health Agency of Canada. (2018). *Canadian Antimicrobial Resistance Surveillance System 2017 Report*.
- Public Health England. (2017). English Surveillance Programme for Antimicrobial Utilisation
 and Resistance (ESPAUR) 2017.
- 398 Rosenfeld, R. M., Piccirillo, J. F., Chandrasekhar, S. S., Brook, I., Ashok Kumar, K., Kramper,
- 399 M., ... Corrigan, M. D. (2015). Clinical Practice Guideline (Update): Adult Sinusitis.

400 *Otolaryngology–Head and Neck Surgery*, *152*(2_suppl), S1–S39.

- 401 https://doi.org/10.1177/0194599815572097
- 402 Sakoulas, G., Geriak, M., & Nizet, V. (2018). Is a Reported Penicillin Allergy Sufficient
- 403 Grounds to Forgo the Multidimensional Antimicrobial Benefits of β -Lactam Antibiotics?

404 Clinical Infectious Diseases, 68, 157–164. https://doi.org/10.1093/cid/ciy557

- 405 Sande, M. A., & Gwaltney, J. M. (2004). Acute Community-Acquired Bacterial Sinusitis:
- 406 Continuing Challenges and Current Management. *Clinical Infectious Diseases*,
- 407 *39*(Supplement_3), S151–S158. https://doi.org/10.1086/421353
- 408 Shehab, N., Patel, P. R., Srinivasan, A., & Budnitz, D. S. (2008). Emergency Department Visits
- 409 for Antibiotic-Associated Adverse Events. *Clinical Infectious Diseases*, 47(6), 735–743.
 410 https://doi.org/10.1086/591126
- 411 Smith, S. S., Evans, C. T., Tan, B. K., Chandra, R. K., Smith, S. B., & Kern, R. C. (2013).
- 412 National burden of antibiotic use for adult rhinosinusitis. *Journal of Allergy and Clinical*

413 *Immunology*, *132*(5), 1230–1232. https://doi.org/10.1016/j.jaci.2013.07.009

- 414 Snow, V., Mottur-Pilson, C., Hickner, J. M., & for the American College of Physicians-
- 415 American Society of Internal Medicine*. (2001). Principles of Appropriate Antibiotic
- 416 Use for Acute Sinusitis in Adults. *Annals of Internal Medicine*, 134(6), 495.

417 https://doi.org/10.7326/0003-4819-134-6-200103200-00016

- 418 Stewardson, A. J., Gaïa, N., François, P., Malhotra-Kumar, S., Delémont, C., Martinez de
- 419 Tejada, B., ... Lazarevic, V. (2015). Collateral damage from oral ciprofloxacin versus
- 420 nitrofurantoin in outpatients with urinary tract infections: A culture-free analysis of gut
- 421 microbiota. *Clinical Microbiology and Infection*, *21*(4), 344.e1-344.e11.
- 422 https://doi.org/10.1016/j.cmi.2014.11.016

423	Swedres-Svarm.	(2017)	. Consumption of	of antibiotics and	l occurrence of	f antibiotic	resistance in

- 424 *Sweden*. Public Health Agency of Sweden and National Veterinary Institute.
- 425 Tedijanto, C., Olesen, S. W., Grad, Y. H., & Lipsitch, M. (2018). Estimating the proportion of
- 426 bystander selection for antibiotic resistance among potentially pathogenic bacterial flora.
- 427 *Proceedings of the National Academy of Sciences*, *115*(51), E11988–E11995.
- 428 https://doi.org/10.1073/pnas.1810840115
- The Human Microbiome Project Consortium. (2012). A framework for human microbiome
 research. *Nature*, 486(7402), 215–221. https://doi.org/10.1038/nature11209
- 431 Tobia, C., Aspinall, S., Good, C., Fine, M., & Hanlon, J. (2008). Appropriateness of antibiotic
- 432 prescribing in veterans with community-acquired pneumonia, sinusitis, or acute
- 433 exacerbations of chronic bronchitis: A cross-sectional study. *Clinical Therapeutics*,

434 *30*(6), 1135–1144. https://doi.org/10.1016/j.clinthera.2008.06.009

- 435 Tomas, M. E., Getman, D., Donskey, C. J., & Hecker, M. T. (2015). Overdiagnosis of Urinary
- 436 Tract Infection and Underdiagnosis of Sexually Transmitted Infection in Adult Women
- 437 Presenting to an Emergency Department. Journal of Clinical Microbiology, 53(8), 2686–
- 438 2692. https://doi.org/10.1128/JCM.00670-15
- 439 Vanden Eng, J., Marcus, R., Hadler, J. L., Imhoff, B., Vugia, D. J., Cieslak, P. R., ... Besser, R.
- 440 E. (2003). Consumer Attitudes and Use of Antibiotics. *Emerging Infectious Diseases*,
- 441 9(9), 1128–1135. https://doi.org/10.3201/eid0909.020591
- 442 Wald, E. R., Guerra, N., & Byers, C. (1991). Upper Respiratory Tract Infections in Young
- 443 Children: Duration of and Frequency of Complications. *Pediatrics*, 87(2), 129–133.

- 444 Williams, J. W., Simel, D. L., Roberts, L., & Samsa, G. P. (1992). Clinical Evaluation for
- 445 Sinusitis. Annals of Internal Medicine, 117(9), 705–710. https://doi.org/10.7326/0003-
- 446 4819-117-9-705

447

449	Supplementary Materials
450 451 452 453	Title: Potential impact of outpatient stewardship interventions on antibiotic exposures of bacterial pathogens
454 455	Authors: Christine Tedijanto, Yonatan H. Grad, Marc Lipsitch
456 457	Appendix Table 1. Notation, descriptions, and sources for variables in Equation 1.
458 459 460 461 462	Appendix Table 2. Modifications to proportions of unnecessary antibiotic prescriptions based on published etiology studies. Modifications were made if the reported proportion of bacterial cases for a given condition exceeded the estimated proportion of appropriate prescriptions reported in Fleming-Dutra et al.
462 463 464 465 466	Appendix Figure 1. Sensitivity analysis of proportions of avertable exposures across all outpatient conditions when proportion of unnecessary use is applied equally across target and bystander exposures.
467 468 469	Appendix Figure 2. Proportion of avertable exposures when all unnecessary use for outpatient conditions is eliminated against proportion of bystander exposures.
470 471 472	Appendix Figure 3. Sensitivity analysis for Scenario 3 (elimination of all antibiotic use for acute sinusitis).
473 474 475	Appendix Figure 4. Proportions of avertable exposures using 2010-2011 NAMCS/NHAMCS data with and without NHAMCS outpatient department data.

Variable	Definition	Source
d _{aig}	Number of prescriptions (using nationally representative weights) of antibiotic a associated with ICD9-CM diagnosis code i in age group g	NAMCS/NHAMCS 2015
esig	Proportion of cases of condition defined by ICD9- CM diagnosis code i in age group g caused by species s	Published etiology studies
p _{s0g}	Asymptomatic carriage prevalence of species s in age group g	Human Microbiome Project (HMP) and published carriage studies
<i>p</i> sig	Carriage prevalence of species s among individuals diagnosed with ICD9-CM code i in age group g	$e_{sig} + (1 - e_{sig})p_{s0g}$
q aig	Proportion of prescriptions of antibiotic a associated with ICD9-CM diagnosis code i in age group g that are avertable under the given scenario	Fleming-Dutra et al. 2016 (Fleming-Dutra et al., 2016); note that this variable is only dependent on <i>a</i> in the nitrofurantoin-specific scenario
Xas	Number of exposures of antibiotic <i>a</i> experienced by species <i>s</i> that are avertable under the given scenario	$\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig} \times q_{aig}$
Tas	Total number of exposures of antibiotic a experienced by species s	$\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig}$

476	Appendix Tal	ble 1. Notation,	descriptions,	and sources	for	variables in Eq	uation 1.

479 Appendix Table 2. Modifications to proportions of unnecessary antibiotic prescriptions based

480 on published etiology studies and antibiotic use in NAMCS/NHAMCS. Modifications were

481 made if the reported proportion of bacterial cases for a given condition exceeded the estimated

482 proportion of appropriate prescriptions reported in Fleming-Dutra et al. (Fleming-Dutra et al.,


483 2016)

Age group	Fleming-Dutra estimate	New estimate	Explanation			
Pharyngitis						
0-19 years old	34%	Pharyngitis: 48%; Strep throat: 0%	Assuming that all strep-associated use of our antibiotics of interest (based on			
20-64 years old	75%	Updated to 58% overall; Pharyngitis: 100%; Strep throat: 0%	NAMCS/NHAMCS) was necessary, we estimated the proportion of non-strep pharyngitis antibiotic use that would have to be eliminated to maintain the overall estimate reported by Fleming- Dutra et al. (Fleming-Dutra et al., 2016)			
>64 years old	NA (assume 0%)	NA (assume 0%)	No change.			
Sinusitis						
0-19 years old	9%	Acute: 16%; Chronic: 0%	While acute sinusitis is rarely bacterial, bacteria are believed to play a much			
20-64 years old	51%	Updated to 40% overall; Acute: 100%; Chronic: 0%	more prominent role in the etiology of chronic sinusitis (Brook, 2016). Thus, we assume that antibiotic use would only be eliminated from acute sinusitis and maintain the overall estimate of			
>64 years old	16%	Acute: 34%; Chronic: 0%	unnecessary use reported by Fleming- Dutra et al. (Fleming-Dutra et al., 2016) when possible.			
Suppurative otitis media						
0-19 years old	10%	10%	No change. Approximately 84% of pediatric cases were found to have bacterial growth (Bluestone, Stephenson, & Martin, 1992), so 10% is a reasonable estimate for avertable use.			
20-64 years old	33%	26%	Based on an etiology study in adults, only 26% of cases were found to have no bacterial growth (Celin, 1991).			
>64 years old	NA (assume 0%)	NA (assume 0%)	No change.			

486 Appendix Figure 1. Sensitivity analysis of proportions of avertable exposures across all

487 outpatient conditions when proportion of unnecessary use is applied equally across target and488 bystander exposures (Equation 1 without modification).

489



490 491

492 Abbreviations: Antibiotics (y-axis): AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,

493 AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,

494 CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,


495 TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin;

496 Organisms (x-axis): EC=E. coli, HI=H. influenzae, KP=K. pneumoniae, MC=M. catarrhalis, PA=P. aeruginosa,

497 SA=S. aureus, SAg=S. agalactiae, SP=S. pneumoniae, SPy=S. pyogenes; PY=person-years

499 **Appendix Figure 2.** Proportion of avertable exposures when all unnecessary use for outpatient 500 conditions is eliminated against proportion of bystander exposures (Tedijanto et al., 2018).


501



- 505 Appendix Figure 3. Sensitivity analysis for Scenario 3 (elimination of all antibiotic use for
- 506 acute sinusitis).

507 A. Use estimates of bacterial etiology to approximate appropriate antibiotic use for acute


- 508 **sinusitis.** The following upper bound estimates for the proportion of acute sinusitis cases with
- 509 bacterial etiology were used: 2% for adults and 13% for children (applied to 0-19 year old age
- 510 group) (Sande & Gwaltney, 2004; Snow, Mottur-Pilson, Hickner, & for the American College of
- 511 Physicians–American Society of Internal Medicine*, 2001; Wald, Guerra, & Byers, 1991).



512

513 **B.** Use estimates of bacterial etiology among those presenting to primary care clinics.

- 514 Patients visiting the clinic are likely to have more persistent, severe, or worsening symptoms,
- 515 which may be indications of bacterial etiology. Studies have estimated that approximately 38%
- 516 of adults and 17% of children (upper bounds) visiting primary care for symptoms of acute upper
- 517 respiratory tract infection have bacterial rhinosinusitis (Aitken & Taylor, 1998; Benninger,
- 518 Holzer, & Lau, 2000; Williams, Simel, Roberts, & Samsa, 1992).




- Abbreviations: Antibiotics (y-axis): AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,
- AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,
- CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,
- TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin; Organisms (x-axis):
- 521 522 523 524 525 526 EC=E. coli, HI=H. influenzae, KP=K. pneumoniae, MC=M. catarrhalis, PA=P. aeruginosa, SA=S. aureus, SAg=S. agalactiae,
- SP=S. pneumoniae, SPy=S. pyogenes; PY=person-years


- 527 Appendix Figure 4. Proportions of avertable exposures using 2010-2011 NAMCS/NHAMCS
- 528 data with *(left)* and without *(right)* NHAMCS outpatient department data.

AMX 948.8 AMX 413.8 AMX-CLA AMX-CLAV PEN PEN 105.1 PENICILLINS 1519.6 PENICILLINS 384.3 AZN AZN CLI CLI 163.2 CLR 76 CLR MACR/LINC MACR/LINC 1288.7 179.9 CIF 449.2 191.5 CIF LEV 20 LEV 20 179.2 MXF 176.3 MXF 165.5 LONES 896.9 NOLONES 830.8 CFL CFL CDR 199.4 CDR 184.8 OSPORING 1022.4 RINS 948.1 DOX DOX 287.0 261.4 TET 23.2 TET 21.2 MNG TETRACYCLINES TETRACYCLINES 379.6 347 5 TMP-SMX NIT TMP-SMX 466.7 421.1 12 MC 11 HI 11 SA NIT 12 MC 149.3 11 SA 136.7 9 EC 9 EC y KP PA SAg SAg SF PA SF 530


529 A. Eliminate unnecessary antibiotic use across all outpatient conditions.




532 are not indicated.



534 C. Eliminate all antibiotic use for acute sinusitis.





537 D. Prescribe nitrofurantoin for all cases of cystitis in women.

Abbreviations: Antibiotics (y-axis): AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,

AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,

- CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,
- TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin; Organisms (x-axis):

544 EC=E. coli, HI=H. influenzae, KP=K. pneumoniae, MC=M. catarrhalis, PA=P. aeruginosa, SA=S. aureus, SAg=S. agalactiae,

545 SP=S. pneumoniae, SPy=S. pyogenes; PY=person-years